Immutep Ltd ADR (IMMP)

$0.57 +0.00 (0.37%)
Market Cap 84.44M
Revenue (ttm) 6.69M
Net Income (ttm) -39.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -594.62%
Debt to Equity Ratio 0.01
Volume 1,887,900
Avg Vol 17,482,230
Day's Range N/A - N/A
Shares Out 147.37M
Stochastic %K 36%
Beta 2.16
Analysts Sell
Price Target $1.00

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
Forsakentrades2024
Forsakentrades2024 Apr. 25 at 12:43 AM
$IMMP just need news here like seriously I want out this
1 · Reply
Hurtadogoalkeeper
Hurtadogoalkeeper Apr. 23 at 1:30 PM
$IMMP Yesterday news. https://www.immutep.com/immutep-announces-abstract-accepted-for-presentation-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting/
0 · Reply
Thylacine4449
Thylacine4449 Apr. 23 at 11:09 AM
$IMMP over 1600% borrow rate something has to give
0 · Reply
2026waves
2026waves Apr. 23 at 5:51 AM
$IMMP It’s fascinating to watch the sentiment shift from extremely bullish to max bearish. A squeeze is coming at some point, I’m sure of it.
1 · Reply
2026waves
2026waves Apr. 22 at 8:13 PM
$IMMP If there isn't a massive rally in the Australian market tonight, I'm clueless
3 · Reply
2026waves
2026waves Apr. 22 at 8:08 PM
$IMMP
0 · Reply
DanTDan
DanTDan Apr. 22 at 6:59 PM
$TLRY this moron is down 50% on $IMMP ... good luck
2 · Reply
focafoca99
focafoca99 Apr. 22 at 6:30 PM
$IMMP was the subject of a Rosen Law Firm notice encouraging investors to inquire about a potential securities class action.
0 · Reply
NOCKNOCK
NOCKNOCK Apr. 22 at 5:14 PM
$IMMP and once again, 0 from the mark et moron.
0 · Reply
EZ_Money11
EZ_Money11 Apr. 22 at 5:13 PM
$IMMP I’m not selling with a 1500% borrow fee….🔥🩳
0 · Reply
Latest News on IMMP
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Sat, 25 Apr 2026 03:05:00 -0400 - 1 day ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Thu, 23 Apr 2026 16:54:00 -0400 - 2 days ago

ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Wed, 22 Apr 2026 13:41:00 -0400 - 3 days ago

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Tue, 21 Apr 2026 17:08:00 -0400 - 4 days ago

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

Tue, 21 Apr 2026 17:01:00 -0400 - 4 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

ROSEN, A TOP RANKED LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Mon, 20 Apr 2026 15:58:00 -0400 - 5 days ago

ROSEN, A TOP RANKED LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Mon, 20 Apr 2026 02:05:00 -0400 - 6 days ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Sat, 18 Apr 2026 22:52:00 -0400 - 7 days ago

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

Thu, 16 Apr 2026 10:00:00 -0400 - 9 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

Immutep Receives FDA Orphan Drug Designation For Efti In Soft Tissue Sarcoma; Stock Up

2026-04-15T18:37:15.000Z - 10 days ago

Immutep Receives FDA Orphan Drug Designation For Efti In Soft Tissue Sarcoma; Stock Up

Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings

2026-04-15T17:25:41.000Z - 10 days ago

Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings

Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doubles

Apr 15, 2026, 12:40 PM EDT - 10 days ago

Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doubles

IMMP

IMMP Investor Alert: Immutep Ltd. Securities Fraud Investigation - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Material Risks Related To Trial Viability : Levi & Korsinsky

Wed, 15 Apr 2026 09:00:00 -0400 - 10 days ago

IMMP Investor Alert: Immutep Ltd. Securities Fraud Investigation - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Material Risks Related To Trial Viability : Levi & Korsinsky

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

Apr 15, 2026, 8:00 AM EDT - 10 days ago

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

IMMP

Why NN Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

2026-04-15T08:51:43.000Z - 11 days ago

Why NN Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Tue, 07 Apr 2026 15:07:00 -0400 - 18 days ago

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Investors in Immutep Limited (IMMP) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today

Mon, 06 Apr 2026 00:12:00 -0400 - 20 days ago

Investors in Immutep Limited (IMMP) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today

Immutep Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Sun, 05 Apr 2026 16:55:00 -0400 - 20 days ago

Immutep Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

ROSEN, LEADING GLOBAL COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Fri, 03 Apr 2026 15:03:00 -0400 - 22 days ago

ROSEN, LEADING GLOBAL COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

ROSEN, A NATIONALLY RECOGNIZED INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Wed, 01 Apr 2026 17:45:00 -0400 - 24 days ago

ROSEN, A NATIONALLY RECOGNIZED INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky

Wed, 01 Apr 2026 09:00:00 -0400 - 24 days ago

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky

Lost Money on Immutep Limited (IMMP)? Possible Fraud - Contact Levi & Korsinsky Today

Mon, 30 Mar 2026 00:14:00 -0400 - 27 days ago

Lost Money on Immutep Limited (IMMP)? Possible Fraud - Contact Levi & Korsinsky Today

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Sun, 29 Mar 2026 23:31:00 -0400 - 27 days ago

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Wed, 25 Mar 2026 17:27:00 -0400 - 4 weeks ago

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Fraud Investigation: Levi & Korsinsky Investigates Immutep Limited (IMMP) on Behalf of Shareholders

Mon, 23 Mar 2026 00:11:00 -0400 - 4 weeks ago

Fraud Investigation: Levi & Korsinsky Investigates Immutep Limited (IMMP) on Behalf of Shareholders

ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Sun, 22 Mar 2026 21:04:00 -0400 - 4 weeks ago

ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm

Mar 20, 2026, 8:00 PM EDT - 5 weeks ago

IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm

IMMP

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Trial Progress: Levi & Korsinsky

Wed, 18 Mar 2026 17:28:00 -0400 - 5 weeks ago

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Trial Progress: Levi & Korsinsky

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP

Tue, 17 Mar 2026 15:15:00 -0400 - 5 weeks ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP

Ongoing Investigation into Immutep Limited (IMMP): Contact Levi & Korsinsky About Potential Fraud

Tue, 17 Mar 2026 11:46:00 -0400 - 5 weeks ago

Ongoing Investigation into Immutep Limited (IMMP): Contact Levi & Korsinsky About Potential Fraud

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 16, 2026, 8:03 AM EDT - 5 weeks ago

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

IMMP

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Feb 6, 2026, 8:00 AM EST - 2 months ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

IMMP

Immutep Quarterly Activities Report Q2 FY26

Jan 29, 2026, 8:00 AM EST - 3 months ago

Immutep Quarterly Activities Report Q2 FY26

IMMP

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Dec 22, 2025, 8:00 AM EST - 4 months ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

IMMP

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Dec 8, 2025, 2:34 AM EST - 4 months ago

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

IMMP

Immutep Transcript: AGM 2025

Nov 26, 2025, 7:30 PM EST - 5 months ago

Immutep Transcript: AGM 2025

Immutep Transcript: Bell Potter Healthcare Conference 2025

Nov 19, 2025, 5:00 PM EST - 5 months ago

Immutep Transcript: Bell Potter Healthcare Conference 2025

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Oct 20, 2025, 8:01 AM EDT - 6 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

IMMP

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

IMMP

Immutep Quarterly Activities Report Q4 FY25

Jul 30, 2025, 8:00 AM EDT - 9 months ago

Immutep Quarterly Activities Report Q4 FY25

IMMP

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Jul 29, 2025, 8:00 AM EDT - 9 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

IMMP

Immutep Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 11 months ago

Immutep Transcript: Jefferies Global Healthcare Conference 2025

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

May 27, 2025, 8:00 AM EDT - 11 months ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

IMMP

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

May 15, 2025, 3:50 PM EDT - 1 year ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

IMMP

Immutep to Participate in Upcoming Investor Conferences

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immutep to Participate in Upcoming Investor Conferences

IMMP

Immutep Quarterly Activities Report Q2 FY25

Jan 31, 2025, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY25

IMMP

Immutep Transcript: Baird's Biotech Discovery Series

Dec 19, 2024, 10:15 AM EST - 1 year ago

Immutep Transcript: Baird's Biotech Discovery Series

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 17, 2024, 8:00 AM EST - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

IMMP

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Dec 12, 2024, 8:15 AM EST - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

IMMP

Immutep Transcript: AGM 2024

Nov 21, 2024, 6:30 PM EST - 1 year ago

Immutep Transcript: AGM 2024

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Nov 14, 2024, 11:16 AM EST - 1 year ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Nov 14, 2024, 8:15 AM EST - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q1 FY25

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Quarterly Activities Report Q4 FY24

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 11, 2024, 6:40 PM EDT - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jul 3, 2024, 8:00 AM EDT - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 5, 2024, 6:00 AM EDT - 2 years ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Jun 2, 2024, 8:38 PM EDT - 2 years ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

May 2, 2024, 8:00 AM EDT - 2 years ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Quarterly Activities Report Q3 FY24

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q3 FY24

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Mar 5, 2024, 8:00 AM EST - 2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Quarterly Activities Report Q2 FY24

Jan 30, 2024, 8:00 AM EST - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 4, 2024, 8:00 AM EST - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 21, 2023, 8:00 AM EST - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Dec 7, 2023, 8:00 AM EST - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 9, 2023, 8:00 AM EST - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 6, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep to Participate in November Investor Events

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Immutep to Participate in November Investor Events

Immutep Quarterly Activities Report Q1 FY24

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q1 FY24

Forsakentrades2024
Forsakentrades2024 Apr. 25 at 12:43 AM
$IMMP just need news here like seriously I want out this
1 · Reply
Hurtadogoalkeeper
Hurtadogoalkeeper Apr. 23 at 1:30 PM
$IMMP Yesterday news. https://www.immutep.com/immutep-announces-abstract-accepted-for-presentation-at-the-american-society-of-clinical-oncology-asco-2026-annual-meeting/
0 · Reply
Thylacine4449
Thylacine4449 Apr. 23 at 11:09 AM
$IMMP over 1600% borrow rate something has to give
0 · Reply
2026waves
2026waves Apr. 23 at 5:51 AM
$IMMP It’s fascinating to watch the sentiment shift from extremely bullish to max bearish. A squeeze is coming at some point, I’m sure of it.
1 · Reply
2026waves
2026waves Apr. 22 at 8:13 PM
$IMMP If there isn't a massive rally in the Australian market tonight, I'm clueless
3 · Reply
2026waves
2026waves Apr. 22 at 8:08 PM
$IMMP
0 · Reply
DanTDan
DanTDan Apr. 22 at 6:59 PM
$TLRY this moron is down 50% on $IMMP ... good luck
2 · Reply
focafoca99
focafoca99 Apr. 22 at 6:30 PM
$IMMP was the subject of a Rosen Law Firm notice encouraging investors to inquire about a potential securities class action.
0 · Reply
NOCKNOCK
NOCKNOCK Apr. 22 at 5:14 PM
$IMMP and once again, 0 from the mark et moron.
0 · Reply
EZ_Money11
EZ_Money11 Apr. 22 at 5:13 PM
$IMMP I’m not selling with a 1500% borrow fee….🔥🩳
0 · Reply
patricius
patricius Apr. 22 at 1:03 PM
$IMMP need a reason to buy...
1 · Reply
GABBYGIRL
GABBYGIRL Apr. 22 at 12:22 PM
$IMMP Another positive PR! https://dilution.news/80e536e4959a0ef84de36b3e5c9625ee
0 · Reply
theinvestaar
theinvestaar Apr. 22 at 2:29 AM
$IMMP News!!!!!!
2 · Reply
dogood
dogood Apr. 21 at 5:08 PM
$ARTL let’s turn green folks $ARTL $WLDS $IMMP $CYCU $CMND
0 · Reply
2026waves
2026waves Apr. 21 at 12:01 PM
$IMMP $BYND
0 · Reply
dogood
dogood Apr. 21 at 11:36 AM
$IMMP is she going to break .75 today?
0 · Reply
AudriusUK
AudriusUK Apr. 21 at 6:52 AM
$IMMP why woud this go up ? what value of share expected in next month ?
1 · Reply
SpaceRunners
SpaceRunners Apr. 20 at 10:56 PM
$VISN $FRMM $ONFO $IMMP ><
0 · Reply
theinvestaar
theinvestaar Apr. 20 at 9:44 PM
$IMMP News tonight. in my experience over there many many many years. The stock never has increases or activity without next day news. I expect to see something after 8 o'clock Eastern
2 · Reply
InTheMoney_
InTheMoney_ Apr. 20 at 9:04 PM
$SPY $QQQ —> $IMMP is getting shorted very hard after the price increase. Cost to borrow is 909% above the 30-day average http://finshort.com/IMMP/cost-to-borrow
0 · Reply
2026waves
2026waves Apr. 20 at 8:38 PM
$IMMP $BYND 🧑‍🚀🧑‍🚀🧑‍🚀
0 · Reply
RunnerSignals
RunnerSignals Apr. 20 at 8:12 PM
top market warriors $PLUG $INV $CAR $ABSI $IMMP flipped red to green. INV +37% and CAR +28% from lows on multi-x volume signal accumulation, PLUG strong but mixed
0 · Reply